Multiform-based Baduanjin exercise prevention and treatment for idiopathic pulmonary fibrosis: study protocol for a randomized controlled trial

Author:

Wu Zenan,Hu Zehao,Ke Shiwen,Mo Lisha,Qiu Mingliang,Zhu Guoshuang,Zhu Wei,Liu Liangji

Abstract

Abstract Introduction In this study, we will combine the traditional Baduanjin with Yijin Jing and Wuqinxi to create an optimized Baduanjin exercise program with three different forms (vertical, sitting, and horizontal) to adapt to idiopathic pulmonary fibrosis (IPF) patients in vairous stages of the disease. The purpose of this study is to explore and compare the therapeutic effects of this multi-form Baduanjin, traditional Baduanjin, and resistance training on lung function and limb motor function in IPF patients. The goal of this study is to prove a novel optimal exercise prescription strategy of Baduanjin exercise for improving and protecting lung function in IPF patients. Methods/design A single-blind and randomized controlled trial is used to conduct this study, while the randomization list will be generated using a computerized random number generator and opaque sealed envelopes with group allocation will be prepared. It will be strictly followed to blind the outcome assessors. and until the experiment’s conclusion, participants won’t know which group they are enrolled in. Patients between the ages of 35 and 80 who have stable diseases and have not regularly practiced Baduanjin exercise in the past will be included. They are divvied up into the following five groups at random: (1) The conventional care group (control group, CG), (2) The traditional Baduanjin exercise group (TG), (3) The modified Baduanjin exercise group (IG), (4) The resistance exercise group (RG) (5) The modified Baduanjin exercise combined with resistance exercise group (IRG). Those CG participants only received the usual treatment, while TC, IG, and RG participants exercised 1 h twice a day for 3 months. MRG participants will have a 3-month intervention with 1 h of Modified Baduanjin Exercise and 1 H of Resistance Training for each day. Every week, all groups underwent will supervis one-day training, with the exception of the control group. The Pulmonary Function Testing (PFT), HRCT, and 6MWT are the main outcome variables. The St. George Respiratory Questionnaire and mMRC are used as secondary outcome measures. Discussion This study may produce a new Baduanjin exercise prescription that is user-friendly, simple to execute, more targeted, and adaptable. Because it consists of three forms, including vertical, sitting, and horizontal, it is more adaptable to the various disease stages and actual situations of IPF patients and may compensate for the shortcomings of conventional pulmonary rehabilitation and traditional Baduanjin. Trial registration Chinese Clinical Trial Registry, ChiCTR2200055559. Registered on 12 January 2022.

Funder

Natural Science Foundation of Jiangxi Province

jiangxi Clinical Medical Research Center of Lung Diseases

Jiangxi Provincial Key Laboratory of Traditional Chinese Medicine Epidemic Diseases

Clinical Study on the Treatment of COVID-19 with Traditional Chinese Medicine

Jiangxi University of Chinese Medicine Science and Technology Innovation Team Development Program

Publisher

Springer Science and Business Media LLC

Subject

Complementary and alternative medicine

Reference34 articles.

1. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566–72. Epub 2014/05/31. https://doi.org/10.1016/S2213-2600(14)70101-8. PubMed PMID: 24875841.

2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 2006;174(7):810-6. Epub 2006/07/01. https://doi.org/10.1164/rccm.200602-163OC. PubMed PMID: 16809633.

3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American journal of respiratory and critical care medicine. 2011;183(6):788–824. Epub 2011/04/08. https://doi.org/10.1164/rccm.2009-040GL. PubMed PMID: 21471066; PubMed Central PMCID: PMCPMC5450933.

4. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2018;198(5):e44-e68. Epub 2018/09/01. https://doi.org/10.1164/rccm.201807-1255ST. PubMed PMID: 30168753.

5. Sakamoto N, Hamada N, Okamoto M, Tobino K, Ichiyasu H, Ishii H, et al. Efficacy and safety of nintedanib in japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study. BMJ Open. 2021;11(6):e047249. Epub 2021/07/01. https://doi.org/10.1136/bmjopen-2020-047249. PubMed PMID: 34187824; PubMed Central PMCID: PMCPMC8245432.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3